Crystalline Forms of Dimethoxy Docetaxel and Methods for Preparing the Same
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/FR2009/000042, filed Jan 15, 2009. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,378,128 | Crystalline Forms of Dimethoxy Docetaxel and Methods for Preparing the Same In force · High confidence | Aventis Pharma S.A. | In force | High confidence | ||
| US 10,160,739 | Crystalline Forms of Dimethoxy Docetaxel and Methods for Preparing the Same In force · High confidence | Aventis Pharma S.A. | In force | High confidence | ||
| US 8,846,959 | Crystalline Forms of Dimethoxy Docetaxel and Methods for Preparing the Same Lapsed Sep 30, 2026 on the fee record Ended Sep 30, 2026 · Medium confidence | Aventis Pharma S.A. | Lapsed Sep 30, 2026 on the fee record | Ended Sep 30, 2026 | Medium confidence | |
| Application 14/453,087 | Crystalline Forms of Dimethoxy Docetaxel and Methods for Preparing the Same Abandoned Abandoned Jul 13, 2017 | Aventis Pharma S.A. | Abandoned | Abandoned Jul 13, 2017 | ||
| Application 16/188,687 | Crystalline Forms of Dimethoxy Docetaxel and Methods for Preparing the Same Abandoned Abandoned Jun 9, 2020 | Aventis Pharma S.A. | Abandoned | Abandoned Jun 9, 2020 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Aventis Pharma S.A..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.